Daily weight-loss pill with low side effects advances toward US sale
A once-a-day, low-impact oral GLP-1 pill known as CX11 has passed its efficacy test on US patients to advance to the first North American Phase 3 trial. It's already cleared its first Phase 3 study in China.Continue ReadingCategory: Obesity, Illnesses and conditions, Body and MindTags: GLP-1 receptor agonists, Weight Loss, clinical trials, Fat cells, peptide, Pharmaceuticals, BioLogic, Experimental, Obesity
Original Source
Read the full article at Refractor →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.